Executive Summary
Overview
flowchart TD
investment_priority_research_a["Priority Research Areas for Neurodegenerative Di"]
style investment_priority_research_a fill:#4fc3f7,stroke:#333,color:#000
investment_priority__0["Executive Summary"]
investment_priority_research_a -->|"includes"| investment_priority__0
style investment_priority__0 fill:#81c784,stroke:#333,color:#000
investment_priority__1["Cross-Disease Gap Analysis"]
investment_priority_research_a -->|"includes"| investment_priority__1
style investment_priority__1 fill:#ef5350,stroke:#333,color:#000
investment_priority__2["Clinical Trial Portfolio Metrics"]
investment_priority_research_a -->|"includes"| investment_priority__2
style investment_priority__2 fill:#ffd54f,stroke:#333,color:#000
investment_priority__3["Critical Gaps Identified"]
investment_priority_research_a -->|"includes"| investment_priority__3
style investment_priority__3 fill:#ce93d8,stroke:#333,color:#000
investment_priority__4["Priority Area 1: Combination Therapies"]
investment_priority_research_a -->|"includes"| investment_priority__4
style investment_priority__4 fill:#4fc3f7,stroke:#333,color:#000
investment_priority__5["Rationale"]
investment_priority_research_a -->|"includes"| investment_priority__5
style investment_priority__5 fill:#81c784,stroke:#333,color:#000
...Executive Summary
Overview
Mermaid diagram (expand to render)
This page identifies priority research areas for neurodegenerative disease R&D, focusing on therapeutic targets, mechanistic pathways, and strategic investment opportunities. The analysis considers disease burden, scientific tractability, and commercial potential.
This page identifies priority research areas based on gap analysis of the current clinical trial landscape across neurodegenerative diseases. Analysis of [ClinicalTrials.gov](https://clinicaltrials.gov) data reveals significant unmet needs and investment opportunities. [@clinicaltrialsgov2026]
Cross-Disease Gap Analysis
Clinical Trial Portfolio Metrics
| Disease | Total Trials | Active Trials | Late-Stage (Phase 3/4) | Biomarker Programs | Investment Landscape |
|---|---|---|---|---|---|
| [Alzheimer's Disease](/diseases/alzheimers-disease) | 4,910 | 1,208 (24.6%) | 489 (10.0%) | 453 (9.2%) | [View](/investment/alzheimers) |
| [Parkinson's Disease](/diseases/parkinsons-disease) | 4,613 | 1,061 (23.0%) | 437 (9.5%) | 254 (5.5%) | [View](/investment/parkinsons) |
| [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) | 1,569 | 434 (27.7%) | 91 (5.8%) | 124 (7.9%) | [View](/investment/als) |
| [Frontotemporal Dementia](/diseases/frontotemporal-dementia) | 380 | 124 (32.6%) | 20 (5.3%) | ~30 (7.9%) | [View](/investment/ftd) |
| [Huntington's Disease](/diseases/huntingtons) | 285 | 66 (23.2%) | 25 (8.8%) | ~20 (7.0%) | [View](/investment/huntingtons) |
Data refreshed: 2026-03-17
Critical Gaps Identified
Low Late-Stage Representation: Phase 3/4 trials represent only 5-10% of total pipeline
Minimal Combination Therapy: 0% combination-therapy signals across major diseases
Biomarker Deficiency: Only 5-9% of trials incorporate biomarker endpoints
Rare Disease Underfunding: MSA, PSP, CBD, and Huntington's have <300 trials each
ALS Funding Gap: Only 91 Phase 3 trials for a uniformly fatal disease
Priority Area 1: Combination Therapies
Rationale
The complete absence of combination-therapy signals in major neurodegenerative disease trials represents a critical gap. Given the multifactorial nature of these diseases, addressing multiple pathological mechanisms simultaneously is likely necessary for disease modification. [@combination2024]
Recommended Approaches
- Amyloid + Tau Combination: Sequential or simultaneous targeting of [amyloid-beta](/proteins/amyloid-beta) and tau pathology
- Neuroinflammation Modulation: Combining anti-amyloid or anti-synuclein approaches with microglial modulators
- Mitochondrial + Protein Aggregation: Dual targeting of mitochondrial dysfunction and protein aggregation
- Synaptic Protection + Disease Modification: Combining neuroprotective agents with disease-modifying therapies
Research Priorities
Phase 2 combination-safety studies for approved monoclonal antibodies
Repurposing existing drugs for combination approaches
Biomarker-driven patient stratification for combination trials
Priority Area 2: Enhanced Biomarker Integration
Rationale
Only 5-9% of current trials incorporate biomarker endpoints, limiting the ability to demonstrate biological activity and select responsive patient populations. [@bloodbased2025]
Recommended Biomarker Focus Areas
- Fluid Biomarkers: CSF and blood-based tau, amyloid, [alpha-synuclein](/proteins/alpha-synuclein), [NfL](/biomarkers/neurofilament-light-chain-nfl)
- Imaging Biomarkers: PET tracers for tau, amyloid, synaptic density
- Digital Biomarkers: wearable-based motor and cognitive monitoring
Research Priorities
Validate fluid biomarker assays for patient selection
Develop blood-based biomarker tests for widespread screening
Establish biomarker-endpoint correlations across disease stages
Priority Area 3: Rare Neurodegenerative Diseases
Rationale
[Multiple System Atrophy](/diseases/multiple-system-atrophy) (MSA), [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) (PSP), [Corticobasal Degeneration](/diseases/corticobasal-degeneration) (CBD), and [Huntington's disease](/diseases/huntington-disease) collectively affect ~100,000-200,000 patients in the US but have minimal trial activity. [@rare2024]
Current Trial Activity
| Disease | Estimated US Prevalence | Active Trials |
|---|---|---:|
| Huntington's Disease | ~30,000 | 66 |
| MSA | ~50,000 | ~30 |
| PSP | ~20,000 | ~25 |
| CBD | ~5,000 | ~15 |
Research Priorities
Huntington's Disease: Focus on gene-silencing approaches (ASO, RNAi) and mitochondrial protectors
MSA/PSP/CBD: Develop alpha-synuclein aggregation inhibitors and neuroprotective agents
Patient Registry Development: Build natural history databases to support trial design
Priority Area 4: [Parkinson's](/diseases/parkinsons-disease) Disease - Non-Motor Symptoms
Rationale
[Parkinson's](/diseases/parkinsons-disease) disease has robust motor symptom coverage but significant gaps in non-motor symptom therapeutics, which often have greater impact on quality of life. [@parkinsons2024]
Unmet Needs
- Cognitive Impairment/Dementia: No approved therapies
- Psychiatric Symptoms: Depression, anxiety, psychosis
- Autonomic Dysfunction: Orthostatic hypotension, gastrointestinal issues
- Sleep Disorders: REM behavior disorder, insomnia
Research Priorities
Alpha-synuclein targeting for cognitive decline prevention
Novel neurotransmitter modulators for psychiatric symptoms
Device-assisted therapies for autonomic dysfunction
Priority Area 5: Disease Modification in ALS
Rationale
ALS has the lowest late-stage representation (5.8%) and smallest overall pipeline, despite being uniformly fatal with median survival of 2-5 years. [@als2025]
Current Challenges
- Only 91 Phase 3 trials total (5.8% of pipeline)
- Highest unmet need across all neurodegenerative diseases
- Limited therapeutic options beyond riluzole and edaravone
Research Priorities
SOD1 and [C9orf72](/entities/c9orf72) Targeting: Continue and expand gene-specific approaches
[TDP-43](/mechanisms/tdp-43-proteinopathy) Pathology: Develop therapies addressing TDP-43 aggregation
Metabolic/Mitochondrial Approaches: Energy metabolism support
Combination Strategies: Multi-target approaches given disease heterogeneity
Priority Area 6: Neuroinflammation as a Therapeutic Target
Rationale
Neuroinflammation is a common feature across all neurodegenerative diseases but remains undertargeted in clinical trials. [@neuroinflammation2024]
Therapeutic Approaches
- Microglial Modulation: [TREM2](/proteins/trem2) agonists, colony-stimulating factor 1 receptor (CSF1R) antagonists
- [NLRP3 Inflammasome](/entities/nlrp3-inflammasome) Inhibition: Small molecule inhibitors
- [Complement System](/entities/complement-system) Modulation: C1q and C3 inhibitors
- Pro-Resolving Mediators: SPMs and specialized pro-resolving mediators
Research Priorities
Biomarker development for neuroinflammation selection
Timing interventions - prophylactic vs. symptomatic
Combination with disease-modifying agents
Priority Area 7: Genetic Risk Factor Targeting
Rationale
Genetic forms of neurodegenerative diseases offer well-validated targets with clear mechanisms. [@genetic2025]
Priority Targets
| Gene | Associated Diseases | Therapeutic Approach |
|---|---|---|
| GBA1 | [Parkinson's](/diseases/parkinsons-disease), Lewy Body Dementia | Gene augmentation, enzyme enhancement |
| LRRK2 | [Parkinson's](/diseases/parkinsons-disease) | Kinase inhibitors, gene silencing |
| SNCA | [Parkinson's](/diseases/parkinsons-disease), MSA | Alpha-synuclein aggregation inhibitors, gene silencing |
| [MAPT](/proteins/tau) | FTD, Alzheimer's | Tau aggregation inhibitors |
| C9orf72 | ALS, FTD | Gene silencing, dipeptide repeat inhibitors |
| [HTT](/proteins/huntingtin) | Huntington's | ASO, RNAi gene silencing |
Research Priorities
Continue gene-specific clinical programs
Develop population-specific genetic therapies
Explore heterozygous dosing for dominant-negative mutations
Implementation Framework
Establish Combination Therapy Working Group: Bring together sponsors, academics, and regulators
Biomarker Validation Consortia: Multi-stakeholder biomarker development
Rare Disease Trial Networks: Build infrastructure for rare neurodegenerative disease trialsMedium-Term Goals (1-3 years)
First Combination Therapy Trials: Initiate Phase 2 combination studies
Biomarker-Enabled Trial Platforms: Adaptive trials with biomarker stratification
Expanded Genetic Screening: Broaden genetic testing in clinical practiceLong-Term Vision (3-5 years)
Precision Medicine Frameworks: Genotype and biomarker-driven treatment selection
Disease-Modifying Combination Standards: Establish standard-of-care combinations
Prevention Trials: Initiate trials in pre-symptomatic genetic carriers
Conclusion
The neurodegenerative disease R&D landscape shows significant gaps in combination therapies, biomarker integration, rare disease research, and non-motor symptom treatment. Addressing these priorities requires coordinated effort across academic, industry, and regulatory stakeholders. The highest-impact investments in the near term would be:
Combination therapy safety and efficacy studies
Biomarker validation and integration
Rare disease trial infrastructure
ALS Phase 3 trial acceleration (only 91 trials for a fatal disease)
Neuroinflammation-targeted therapeutics
Clinical Trials
For current clinical trials across neurodegenerative diseases, see:
- [Clinical Trials Index](/clinical-trials)
- [Clinical Trials: Alzheimer's Disease](/clinical-trials/alzheimers-disease)
- [Clinical Trials: Parkinson's Disease](/clinical-trials/parkinsons-disease)
See Also
- [Alzheimer's Disease Research
- [Parkinson's Disease Research](/researchers/anthony-lang)
- [Neuroinflammation Mechanisms](/content/mechanisms)
- [Investment Landscape Overview](/content/investment)
](/diseases/alzheimers-disease-research
- [National Institute on Aging](https://www.nia.nih.gov/)
- [Michael J. Fox Foundation](https://www.michaeljfox.org/)
- [Alzheimer's Association](https://www.alz.org/)
References
ClinicalTrials.gov Neurodegenerative Disease Pipeline Analysis (2026) (2026)
[Combination Therapy Approaches in Alzheimer's Disease - Nature Reviews Drug Discovery (2024) (2024)](https://doi.org/10.1038/s41573-024-00800-2))
[Blood-Based Biomarkers for Neurodegenerative Diseases - Acta Neuropathologica (2025) (2025)](https://doi.org/10.1007/s00401-025-00345-x))
[Rare Neurodegenerative Disease Epidemiology - Orphanet Journal of Rare Diseases (2024) (2024)](https://doi.org/10.1186/s13023-024-03100-5))
[Parkinson's Disease Non-Motor Symptoms - Lancet Neurology (2024) (2024)](https://doi.org/10.1016/S1474-4422(24))
[ALS Clinical Trials Landscape - Nature Reviews Neurology (2025) (2025)](https://doi.org/10.1038/s41582-025-00900-4))
[Neuroinflammation in Neurodegeneration - Neuron (2024) (2024)](https://doi.org/10.1016/j.neuron.2024.06.015))
[Genetic Forms of Neurodegenerative Diseases - Brain (2025) (2025)](https://doi.org/10.1093/brain/awae180))